Lakewood-Amedex Biotherapeutics Inc Dossier
Qualitative Analysis
Business overview
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology company focused on developing a novel class of fast-acting, broad-spectrum synthetic antimicrobials known as the Bisphosphocin® class. The company's primary objective is to address the global antimicrobial resistance (AMR) crisis by offering therapeutic alternatives that physically disrupt bacterial membranes, thereby presenting a high barrier to resistance development. Its lead drug candidate, Nu-3, is a Phase 2-ready topical gel formulation designed to treat infected diabetic foot ulcers (iDFU), a severe complication affecting millions of diabetic patients worldwide.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead Bisphosphocin® candidate, Nu-3, into clinical trials for mildly infected diabetic foot ulcers (iDFU). The program begins with an open-label, single-blinded Phase 2a study evaluating 2%, 5%, and 10% gel concentrations to establish proof of concept and dose response, followed by a planned double-blind, placebo-controlled Phase 2b trial.
Expected impact: Validation of the Bisphosphocin® platform's physical mechanism of action in humans, paving the way for a registrational pathway in a large, underserved wound care market.
Leveraging the proprietary Bisphosphocin® platform to develop chemically distinct, early-stage pipeline compounds for localized delivery. The company is targeting high-need indications where local administration can bypass systemic side effects.
Expected impact: Identification of optimal treatment candidates for complicated urinary tract infections (cUTI), catheter-associated UTIs (CAUTI), and pulmonary infections (such as CABP, HABP, and cystic fibrosis).
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
PERI will serve as the CRO for the upcoming Phase 2 clinical program of Nu-3. Founded by a practicing podiatrist, PERI provides deep expertise in wound care and diabetic foot ulcers, along with an established network of investigators to support efficient patient recruitment and high-quality data generation.
Terms: Terms not publicly disclosed.